Trial Profile

Phase 2 Study of the MEK Inhibitor MEKTOVI (binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary)
Indications Craniopharyngioma
Focus Therapeutic Use

Most Recent Events

26 Jun 2024 The protocol has been amended to change in time frame.
20 Apr 2023 Planned End Date changed from 15 Mar 2027 to 10 Apr 2027.
20 Apr 2023 Planned primary completion date changed from 15 Mar 2025 to 10 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com